Clinical Trial Update: Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer [Phase 1, Phase 2]

View source ↗

Summary

This is a Phase 1/2 clinical trial evaluating enfortumab vedotin plus pembrolizumab with radiotherapy for muscle-invasive bladder cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer
• Stage Iiia Bladder Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Padcev (enfortumab vedotin)

Snippet

Sponsor: University of California, San Francisco | Conditions: Bladder Cancer, Muscle-Invasive Bladder Carcinoma | Phase 1, Phase 2 | Status: RECRUITING